A large pooled analysis of the FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF trials demonstrated reductions in heart failure hospitalization and composite kidney outcomes, with a notable reduction in all-cause mortality, although the reduction in cardiovascular death did not reach statistical significance [ 32 ].
← all excerpts
Finerenone: A Third-Generation MRA and Its Impact on Cardiovascular Health-Insights from Randomized Controlled Trials.
1
—
—